Module 9 2024

05/09/2024

PD Considerations

Steep part of dose response curve

Endpoint may not need to be validated but must be relevant + show clear dose/concentration response relationship

Occasionally may replace clinical trial

May need to test at several doses

Response Dose

The Organisation for Professionals in Regulatory Affairs

43

IMMUNOGENICITY CONSIDERATIONS

The Organisation for Professionals in Regulatory Affairs

44

22